Company intelligence / Profile preview
Espad Pharmed
- Ownership
- Private
- Employees
- ~374
- Development stage
- Commercial
01
Overview
Currently conducting clinical trials comparing their Lunaphil Ultra (Hyaluronic Acid) product with Juvederm Ultra 4® for treating nasolabial folds, and testing AbobotulinumtoxinA in a non-inferiority clinical trial. The Lunaphil Ultra trial is a randomized, double-masked, active controlled study with 104 participants[4]. The AbobotulinumtoxinA trial is scheduled to continue until April 26, 2025[6].
- Therapeutic areas
- Dermatology
- Modalities
- Hyaluronic acid fillersAbobotulinumtoxinA
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Espad Pharmed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Espad Pharmed.